India’s COVID-19 Nightmare And How Pharma Is Holding Up
A COVID-19 second wave is wreaking havoc in India but pharma appears to be holding things together for now, stretching resources amid a dip in personnel attendance and supply chain strains. Limited vaccine supplies, a spurt in API prices and an inevitable third wave could mean further turbulence ahead.
You may also be interested in...
As the B.1.617 variant of SARS-CoV-2 spreads to countries including the UK and US after having caused havoc in India, vaccine effectiveness against this variant is under the lens with breakthrough cases reported post full vaccination. Meanwhile, CEPI’s offer to help in testing against variants has potential to harmonize assessment of COVID-19 vaccines performance.
In this week's podcast episode of Five Must-Know Things, hear about issues surrounding the proposed IP waiver for coronavirus vaccines, a trial delay for Novavax’s COVID-19 vaccine, an ICER review of multiple myeloma drugs and Galapagos’ efforts to refocus its R&D pipeline.
Drug manufacturers still have a variety of ways to limit the impact of the Biden administration’s historic decision. Whether the huge political loss for industry translates into more than just headline-risk or faster global COVID vaccination remains to be seen. It is also not clear whether it is an ominous sign for other industry battles in the US, including the drug pricing debate.